PE20090224A1 - Combinaciones que comprenden pregabalina - Google Patents

Combinaciones que comprenden pregabalina

Info

Publication number
PE20090224A1
PE20090224A1 PE2008000767A PE2008000767A PE20090224A1 PE 20090224 A1 PE20090224 A1 PE 20090224A1 PE 2008000767 A PE2008000767 A PE 2008000767A PE 2008000767 A PE2008000767 A PE 2008000767A PE 20090224 A1 PE20090224 A1 PE 20090224A1
Authority
PE
Peru
Prior art keywords
amino
combinations including
including pregabalin
methyl
salt
Prior art date
Application number
PE2008000767A
Other languages
English (en)
Inventor
Kevin Paul Gunn
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39684397&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090224(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of PE20090224A1 publication Critical patent/PE20090224A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE PREGABALINA ((S)-(+)-4-AMINO-3-(2-METILPROPIL)BUTANOICO) O UNA SAL DEL MISMO Y 1-(2-ETOXIETIL)-5-[ETIL(METIL)AMINO]-N-MESIL-7-[(4-METIL-2-PIRIDIL)AMINO]-1H-PIRAZOLO[4,3-d]PIRIMIDINA-3-CARBOXAMIDA (INHIBIDOR SELECTIVO DE LA FOSFODIESTERASA 5 (PDE5)) O UNA SAL DE LA MISMA. DICHA COMBINACION ES UTIL EN EL TRATAMIENTO DEL DOLOR
PE2008000767A 2007-05-01 2008-04-29 Combinaciones que comprenden pregabalina PE20090224A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91517407P 2007-05-01 2007-05-01

Publications (1)

Publication Number Publication Date
PE20090224A1 true PE20090224A1 (es) 2009-03-13

Family

ID=39684397

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000767A PE20090224A1 (es) 2007-05-01 2008-04-29 Combinaciones que comprenden pregabalina

Country Status (8)

Country Link
US (1) US20080293746A1 (es)
AR (1) AR066362A1 (es)
CL (1) CL2008001176A1 (es)
PA (1) PA8778901A1 (es)
PE (1) PE20090224A1 (es)
TW (1) TW200904401A (es)
UY (1) UY31062A1 (es)
WO (1) WO2008132589A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals

Also Published As

Publication number Publication date
CL2008001176A1 (es) 2008-11-07
UY31062A1 (es) 2008-11-28
AR066362A1 (es) 2009-08-12
US20080293746A1 (en) 2008-11-27
TW200904401A (en) 2009-02-01
PA8778901A1 (es) 2008-12-18
WO2008132589A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
AR090677A2 (es) Preparacion farmaceutica que contiene oxicodona y naloxona
CL2008000894A1 (es) Composicion para el cuidado oral que comprende un aminoacido basico en forma libre o sal, una sal de fluoruro soluble, una sal de calcio de un acido organico; uso en el tratamiento de dientes desmineralizados y lesiones de esmalte de los dientes de un sujeto.
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
CL2015001694A1 (es) Composicion que comprende un complejo de haluro de zinc tetrabasico-aminoacido o trialquil glicina y cisteina en forma libre o de sal aceptable oralmente o cosmetico; y su uso para eliminar bacterias, reducir la transpiracion y/o el olor corporal, tratar o reducir el acne, limpiar los dientes e inhibir las caries, entre otros.
CL2011001621A1 (es) Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos.
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
CO5660275A2 (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
CU23367A3 (es) Formulación de moxifloxacino con sal común
HK1080447A1 (en) Retinol derivatives, their use in the treatment ofcancer and for potentiating the efficacy of other cytotoxic agents
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
CL2007000945A1 (es) Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea.
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
AU2003303624A1 (en) Use of hygroscopic treatments to enhance dryness in an absorbent article
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
ATE504303T1 (de) Kombination aus roscovitine und cs-682 oder seinem metaboliten cndac
BRPI0410044B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
MY146803A (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
PE20090224A1 (es) Combinaciones que comprenden pregabalina
CL2008000227A1 (es) Composicion farmaceutica que comprende una combinacion de uso oral de tramadol y ketoprofeno; y uso en el tratamiento del dolor.
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
FR2847470B1 (fr) Composition, notamment cosmetique, comprenant l'adenosine et des sels de magnesium et potassium
AR060394A1 (es) Composicion farmaceutica que comprende un analgesico y vitaminas
CL2007001763A1 (es) Composicion farmaceutica en forma de una tableta multicapas que comprende una primera region que comprende una tetraciclina y un vehiculo, y una segunda region que comprende un tampon y un segundo vehiculo; formulacion acuosa; y uso para tratar o prevenir la mucositis oral.
PA8624501A1 (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis

Legal Events

Date Code Title Description
FD Application declared void or lapsed